Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

被引：0
|
作者：
Douglas B. Fox
Richard Y. Ebright
Xin Hong
Hunter C. Russell
Hongshan Guo
Thomas J. LaSalle
Ben S. Wittner
Nicolas Poux
Joanna A. Vuille
Mehmet Toner
Nir Hacohen
Genevieve M. Boland
Debattama R. Sen
Ryan J. Sullivan
Shyamala Maheswaran
Daniel A. Haber
机构：
[1] Massachusetts General Hospital Cancer Center and Harvard Medical School,Center for Engineering in Medicine
[2] Broad Institute of Harvard and MIT,Department of Surgery
[3] Massachusetts General Hospital and Harvard Medical School,Department of Medicine
[4] Shriners Hospitals for Children,Department of Biochemistry, School of Medicine and Key University Laboratory of Metabolism and Health of Guangdong
[5] Massachusetts General Hospital and Harvard Medical School,Liangzhu Laboratory
[6] Massachusetts General Hospital and Harvard Medical School,undefined
[7] Howard Hughes Medical Institute,undefined
[8] Southern University of Science and Technology,undefined
[9] Zhejiang University Medical Center,undefined
来源：
npj Precision Oncology | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional characterization using mouse melanoma models, we show that the KEAP1/NRF2 pathway modulates sensitivity to ICB, independently of tumorigenesis. The NRF2 negative regulator, KEAP1, shows intrinsic variation in expression, leading to tumor heterogeneity and subclonal resistance.
引用
收藏
相关论文
共 50 条
  • [21] A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
    Huang, Alexander C.
    Zappasodi, Roberta
    NATURE IMMUNOLOGY, 2022, 23 (05) : 660 - 670
  • [22] A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
    Alexander C. Huang
    Roberta Zappasodi
    Nature Immunology, 2022, 23 : 660 - 670
  • [23] The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications
    Hargadon, K. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1095 - 1104
  • [24] Predictors of responses to immune checkpoint blockade in advanced melanoma
    Jacquelot, N.
    Roberti, M. P.
    Enot, D. P.
    Rusakiewicz, S.
    Ternes, N.
    Jegou, S.
    Woods, D. M.
    Sodre, A. L.
    Hansen, M.
    Meirow, Y.
    Sade-Feldman, M.
    Burra, A.
    Kwek, S. S.
    Flament, C.
    Messaoudene, M.
    Duong, C. P. M.
    Chen, L.
    Kwon, B. S.
    Anderson, A. C.
    Kuchroo, V. K.
    Weide, B.
    Aubin, F.
    Borg, C.
    Dalle, S.
    Beatrix, O.
    Ayyoub, M.
    Balme, B.
    Tomasic, G.
    Di Giacomo, A. M.
    Maio, M.
    Schadendorf, D.
    Melero, I.
    Dreno, B.
    Khammari, A.
    Dummer, R.
    Levesque, M.
    Koguchi, Y.
    Fong, L.
    Lotem, M.
    Baniyash, M.
    Schmidt, H.
    Svane, I. M.
    Kroemer, G.
    Marabelle, A.
    Michiels, S.
    Cavalcanti, A.
    Smyth, M. J.
    Weber, S.
    Eggermont, A. M.
    Zitvogel, L.
    NATURE COMMUNICATIONS, 2017, 8
  • [25] Melanoma: immune checkpoint blockade story gets better
    Bhatia, Shailender
    Thompson, John A.
    LANCET, 2014, 384 (9948): : 1078 - 1079
  • [26] Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain
    Di Giacomo, Anna Maria
    Margolin, Kim
    SEMINARS IN ONCOLOGY, 2015, 42 (03) : 459 - 465
  • [27] Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
    Bastian Schilling
    Tim Schneider
    Inga Möller
    Antje Sucker
    Annette Paschen
    Dirk Schadendorf
    Klaus G. Griewank
    Journal of Translational Medicine, 13 (Suppl 1)
  • [28] Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
    Sarver, Melissa
    Brown, Michael C.
    Rhodin, Kristen E.
    Salama, April K. S.
    Beasley, Georgia M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (03)
  • [29] Next targets for immune checkpoint blockade in melanoma.
    Chauvin, Joe-Marc
    Ka, Mignane
    Pagliano, Ornella
    Foucade, Julien
    Menna, Carmine
    Davar, Diwakar
    Kirkwood, John
    Kuchroo, Vijay
    Anderson, Ana
    Korman, Alan
    Zarour, Hassane
    CANCER RESEARCH, 2020, 80 (19) : 16 - 16
  • [30] Predictors of responses to immune checkpoint blockade in advanced melanoma
    N. Jacquelot
    M. P. Roberti
    D. P. Enot
    S. Rusakiewicz
    N. Ternès
    S. Jegou
    D. M. Woods
    A. L. Sodré
    M. Hansen
    Y. Meirow
    M. Sade-Feldman
    A. Burra
    S. S. Kwek
    C. Flament
    M. Messaoudene
    C. P. M. Duong
    L. Chen
    B. S. Kwon
    A. C. Anderson
    V. K. Kuchroo
    B. Weide
    F. Aubin
    C. Borg
    S. Dalle
    O. Beatrix
    M. Ayyoub
    B. Balme
    G. Tomasic
    A. M. Di Giacomo
    M. Maio
    D. Schadendorf
    I. Melero
    B. Dréno
    A. Khammari
    R. Dummer
    M. Levesque
    Y. Koguchi
    L. Fong
    M. Lotem
    M. Baniyash
    H. Schmidt
    I. M. Svane
    G. Kroemer
    A. Marabelle
    S. Michiels
    A. Cavalcanti
    M. J. Smyth
    J. S. Weber
    A. M. Eggermont
    L. Zitvogel
    Nature Communications, 8
12345